CIM
CRL icon

Calvert Investment Management’s Charles River Laboratories CRL Stock Holding History

Calvert Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,816
Closed -$215K – 152
2016
Q4 		$215K Sell
2,816
-136
-5% -$10.3K 0.01% 768
2016
Q3 		$246K Buy
2,952
+249
+9% +$20.9K 0.01% 712
2016
Q2 		$223K Buy
+2,703
New +$223K 0.01% 702

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Calvert Investment Management's CRL Position: Q1 2017 in Review

Calvert Investment Management sold out of Charles River Laboratories (CRL) in Q1 2017, closing a stake of 2,816 shares — an estimated $215K sold.

Calvert Investment Management first reported a position in CRL in Q2 2016 and held it in 3 quarters. The position peaked at $246K in Q3 2016. 300 funds tracked by Wall St. Rank hold CRL as of Q1 2017.

  • Calvert Investment Management reported no remaining Charles River Laboratories position as of Q1 2017 after selling out during the quarter.
  • Calvert Investment Management sold 2,816 Charles River Laboratories shares in Q1 2017, an estimated $215K.
  • Calvert Investment Management first reported a position in Charles River Laboratories in Q2 2016 and held it in 3 quarters.
  • Calvert Investment Management's Charles River Laboratories position peaked at $246K in Q3 2016.
  • 300 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2017.

Based on Calvert Investment Management's 13F filing for Q1 2017.